Mission:

THE ELIMINATION OF CANCER AND RELATED DISEASES AS CAUSES OF HUMAN SUFFERING AND DEATH.


 https://www.fredhutch.org/en.html
 |  1100 FAIRVIEW AVE N Seattle WA 98109-4433

Fred Hutchinson Cancer Research Center is headquartered in Seattle, WA, and is a 501(c)(3) organization. EIN: 23-7156071.  Donations are tax-deductible. The IRS' NTEE classification is Cancer Research within the Medical Research category. The IRS ruling year for tax exemption was 1972.

(Source: IRS Business Master File and Form 990)


...  ...  ...  ...  

Encompass Rating System by Charity Navigator


Charity Navigator’s Encompass Rating System evolves on a quarterly basis as we add new measures and indicators, which we call Beacons. Check back often to see how this organization’s score changes.

Learn about the Encompass Rating System: Announcement | FAQ | Release Notes


Overall Score
BETA

100

out of 100

This charity's score is a passing score.

Do you work for Fred Hutchinson Cancer Research Center? Gain access to your rating toolkit.


Looking for this charity in our old design?

Back to Top

...   Finance & Accountability


Charity Navigator evaluates a nonprofit organization’s financial health including measures of stability, efficiency and sustainability. We also track accountability and transparency policies to ensure the good governance and integrity of the organization.


Finance & Accountability Score
BETA

100

out of 100

This charity's score is a passing score

This Beta V1 of Finance Score provides a baseline measure of an organization’s health including the indicators listed in the report below.

This score represents Form 990 data from latest filing year 2018.



Finance & Accountability Rating Highlights

Higher Effect on Score

Board Composition

20/20 Independent

We look for at least 3 board members, with more than 50% of members identified as independent.

Lower Effect on Score

Liabilities to Assets Ratio

40.43%

Charity Navigator looks for a ratio less than 50%.

No Effect on Score

Total Revenue

$851,220,102

Charity Navigator doesn’t evaluate revenue amounts or sources in Beta V1. An organization’s size can affect whether and how we evaluate other indicators.

Back to Top

Finance & Accountability Report

100

of 100 points (BETA)

This beta feature is currently viewable only on desktop or tablet screens. Check back later for updates.

Overview

Overview

The Finance and Accountability Score provides a basic measure for organizational health. At this time, it comprises 100% of a charity's Overall Score.

Program Expense Ratio

92.59%

Higher effect on score

More data  


The Program Expense Ratio is determined by Program Expenses divided by Total Expense (average of most recent three 990s).


For a passing score, Charity Navigator looks for a ratio of 70% or higher. Charities in the 50%-70% range receive zero points for their Program Expense Ratio score. Charities that fall below 50% will receive zero points for both of their financial metric scores, Program Expense Ratio AND Liabilities to Assets Ratio.


Source: IRS Form 990

Board Composition

20/20 Independent

Higher effect on score


Charity Navigator looks for at least 3 board members, with more than 50% of those members identified as independent.


Source: IRS Form 990

Independent Review/Financial Audit

Audited

Higher effect on score


For organizations larger than $1million in total revenue we expect to see that the charity completed an audit.


This indicator is not part of the score for organizations less than $250k in total revenue and is removed from the scoring methodology.


For charities under $1 million but over $250K in total revenue we expect to see that the charity completed an Audit, Review or Compilation.


Source: IRS Form 990

Liabilities to Assets Ratio

40.43%

Lower effect on score


The Liabilities to Assets Ratio is determined by Total Liabilities divided by Total Assets (most recent 990).


Charity Navigator looks for a ratio less than 50%.


Source: IRS Form 990

Website Listed

Listed

Lower effect on score


Charity Navigator looks for a website on the Form 990 as an accountability and transparency measure.


Nonprofits act in the public trust and reporting publicly on activities is an important component


Source: IRS Form 990

Data Sources

IRS Forms 990 are provided courtesy of Foundation Center.

...   Impact & Results


Charity Navigator assesses how well a nonprofit delivers on its mission. To issue an Impact & Results score, we estimate the actual impact a nonprofit has on the lives of those it serves, and determine whether it is making good use of donor resources to achieve that impact.


No Score

We have not issued this nonprofit an Impact & Results score. This does not indicate a positive or negative assessment, only that we have not reached a conclusion for one of the following reasons:

  • The nonprofit is eligible for a score, but we have not yet gotten to scoring it.

  • The nonprofit is eligible for a score, but we have not yet developed the specific algorithms to estimate the impact of the type of service it delivers and so cannot issue a score yet.

  • The nonprofit does not primarily deliver services directly to beneficiaries or it is not reasonable to expect the nonprofit to measure impact for its primary activity. The impact analysis framework that we use is not well suited to these nonprofits.

  • The nonprofit is not heavily reliant on individual donors because beneficiaries fund a majority of its costs or it does not receive any private charitable contributions.

Learn more about how we rate nonprofits.

Do you work at Fred Hutchinson Cancer Research Center? Share your impact data to request a score.


Back to Top

Additional Information

Unscored

This beta feature is currently viewable only on desktop or tablet screens. Check back later for updates.

Largest Programs

Largest Programs



Fred Hutchinson Cancer Research Center reported its three largest programs on its FY 2018 Form 990 as:


$210,354,076

Spent in most recent FY

38%

Percent of program expenses


VACCINE AND INFECTIOUS DISEASE DIVISION (VIDD): VIDD INTEGRATES THE LATEST IN COMPUTATIONAL, LABORATORY AND CLINICAL RESEARCH METHODS TO ADVANCE THE UNDERSTANDING OF MICROBIAL PATHOGENESIS AND INFECTI ... (More)


$149,367,806

Spent in most recent FY

27%

Percent of program expenses


CLINICAL RESEARCH DIVISION: THE CLINICAL RESEARCH DIVISION CONDUCTS LABORATORY AND PATIENT-ORIENTED RESEARCH TO BETTER UNDERSTAND THE MECHANISMS THAT DRIVE CANCER AND OTHER HUMAN DISEASES. INTEGRATING ... (More)


$115,821,542

Spent in most recent FY

21%

Percent of program expenses


PUBLIC HEALTH SCIENCES DIVISION:THE PUBLIC HEALTH SCIENCES DIVISION IDENTIFIES STRATEGIES THAT WOULD ULTIMATELY REDUCE THE INCIDENCE OF AND MORTALITY FROM CANCER AND OTHER DISEASES. USING LARGE POPULA ... (More)


GuideStar Seal of Transparency

Gold


GuideStar is Charity Navigator's trusted partner in sharing information on how this organization seeks impact. GuideStar has recognized this organization with a Gold Seal of Transparency for voluntarily and publicly describing their goals, strategies, and accomplishments. Click here for more information.

Note: GuideStar Seals do not effect the nonprofit’s Impact & Results Score.


What is your organization aiming to accomplish?

Fred Hutchinson Cancer Research Center works to eliminate cancer and related diseases as causes of human suffering and death. To achieve our mission, we conduct fundamental, translational and clinical research that will lead to better cancer prevention, diagnosis and treatment. Recent scientific breakthroughs have brought us to a critical point in the fight against cancer and other diseases. We believe that curative therapies for most if not all cancers can be developed by 2025. In addition to cancer, we research HIV and other life-threatening infections and diseases. We are home to one of the world's largest HIV research units and serve as the hub of the HIV Vaccine Trials Network, a global effort to develop and test a successful HIV vaccine. Our researchers, including three Nobel laureates, bring a relentless pursuit of health, knowledge and hope to their work. They are discovering new ways to prevent cancer; to detect cancer earlier, when cure rates are highest; and to develop effective treatments with fewer side effects.


What are your strategies for making this happen?

Fred Hutch scientists conduct fundamental research on cells and changes in their processes that cause disease, develop and test new types of diagnostics and treatments, and develop and apply new knowledge that helps individuals and communities reduce the incidence and impact of cancer and related diseases. Fred Hutch's scientific priorities are strategically focused on five high-impact areas of cancer and cancer-related disease research: transplant and immunotherapy; cancer etiology, prevention and outcomes; vaccine development and viral cancers; the molecular basis of cancer; and tumor-specific translational research. Fred Hutch is an internationally recognized leader in each of these fields, with deep expertise in cancer prevention, and preclinical and clinical application of new treatments. Our Basic Sciences Division is unparalleled and renders us unique among cancer centers. In addition, Fred Hutch drives collaborative research through Integrated Research Centers (IRCs) that catalyze high-impact, innovative research through cross-divisional collaboration, focusing on cutting-edge, competitive areas that leverage unique Hutch resources and expertise. Recently, Fred Hutch launched an Immunotherapy IRC and a Pathogen-Associated Malignancies IRC, two areas poised for significant breakthroughs. Through our pioneering work in bone marrow transplantation, Fred Hutch became the first research institution to demonstrate the body's ability to harness the immune system. Since that discovery, we have continued to advance the burgeoning field of immunotherapy for cancer and translate these insights to related disciplines. Our Vaccine and Infectious Disease Division, for example, grew out of our experience in bone marrow transplantation and research on the infectious complications that can occur after transplant. Today, Fred Hutch is the only cancer institute in the United States dedicated to eliminating virus-associated malignancies through vaccine development, which we anticipate will have a significant impact on the 20 percent of cancers that have an infectious cause. To seamlessly continue research and care, Fred Hutch works to grow and diversify funding from industry partners and individuals. We are accelerating our commercialization impact by increasing the speed and scale with which we bring our specialized knowledge and technology to commercial markets so that every patient can have access to lifesaving cures. We plan to grow and diversify philanthropic support, and we welcome investment from individual donors who are passionate about delivering the cancer care of tomorrow. We will continue to work with government agencies, leaders and policymakers to maintain and grow support for research funding.


What are your organization's capabilities for doing this?

Our groundbreaking discoveries began in the 1970s with Dr. E. Donnall Thomas' pioneering work in bone marrow transplantation, which earned him the 1990 Nobel Prize in physiology or medicine. More than 1 million bone marrow transplants have since been performed around the world. Fred Hutch researchers have continued to achieve leading-edge breakthroughs, including developing immunotherapies that use the body's immune system to defeat cancer and deepening the understanding of human biology. Today, Fred Hutch is home to five scientific divisions, two Integrated Research Centers, and more than 3,000 staff who work to eliminate cancer and related diseases. Our more than 200 faculty study over 30 diseases through the lenses of fundamental research, prevention, early detection, treatment and survivorship. Our roster of internationally acclaimed scientists includes three Nobel laureates, a MacArthur Fellow, ten members of the National Academy of Sciences, ten members of the Institute of Medicine, eight members of the American Academy of Arts and Sciences, 14 members of the American Association for the Advancement of Science, and nine current and former Howard Hughes Medical Institute investigators. Our research is leading to discoveries, translating discoveries into cures and transforming the lives of millions. Our 15-acre Seattle campus includes state-of-the-art laboratories and inclusive shared resources, which are core facilities that provide services and access to specialized equipment available to all faculty. We strive to ensure that every Fred Hutch laboratory has access to the latest technology and can capitalize on our world-class infrastructure. We also collaborate with scientists and clinicians from leading local academic and research institutions. In 1998, Fred Hutch joined UW Medicine and Seattle Children's to form Seattle Cancer Care Alliance, one of the top-five cancer treatment centers in the U.S. The Fred Hutch/University of Washington Cancer Consortium was formed in 2002 to enhance and accelerate cancer research at Fred Hutch, UW Medicine and Seattle Children's by bringing together 400 faculty with cancer-research interests in the basic, clinical and public health sciences. In addition to local collaborations, Fred Hutch works with national and international partners to address the global impact of cancer, which is projected to grow by nearly 70 percent by 2030. Our research and clinical trials span the globe, touching lives in more than 70 countries. Fred Hutch has formed a unique partnership with the Uganda Cancer Institute, the first comprehensive cancer center jointly built by U.S. and African cancer institutions in sub-Saharan Africa. Fred Hutch's international reach also extends to China, where our China Initiative aims to share scientific data, statistical analysis methods and clinical research developments through research partnerships with organizations such as the Chinese Center for Disease Control and Prevention.


How will your organization know if you are making progress?

Patient outcomes are the most important marker of progress at Fred Hutch, and we strive every day to deliver curative therapies that will benefit patients around the world. Translational research — the process of scaling fundamental research into medical practice — is the cornerstone of our work. Clinical trials are critical to finding new ways to treat diseases and save lives. Each year, hundreds of clinical trials are underway at Fred Hutch, with more waiting for funding. These trials give patients access to the newest treatments and help our investigators develop effective therapies faster. Our progress is marked by the expansion of these trials to bring novel therapies to thousands of patients. Our research is having an increasingly significant impact on the number of people who are affected by cancer, as we learn how to better prevent, diagnose and treat it. For example, when the Hutch-based Women's Health Initiative found that combined hormone therapy dramatically increases breast cancer risk, millions of women stopped taking the drugs, preventing up to 20,000 cases of breast cancer in the U.S. each year. Scientific publications are vital to disseminating the latest research discoveries to other cancer centers, universities and health care facilities. In 2016, Fred Hutch produced 1,356 publications, averaging six publications per faculty member. Fred Hutch papers are cited 2.5 times more often than average. The insights shared through these articles are catalyzing further discoveries across the spectrum of biomedical research.


What have and haven't you accomplished so far?

Our pioneering work in bone marrow and stem cell transplantation in the 1970s has resulted in more than 1 million bone marrow transplants being performed worldwide. It also demonstrated the potential of the immune system to wipe out cancer. Today, we continue to research and refine these and related transplantation techniques. For example, we are evaluating transplants conducted with umbilical cord blood cells, which can overcome limitations associated with bone marrow transplantation, including the requirement for a close donor match. We continue to harness the power of the immune system through a world-leading immunotherapy program. For example, Fred Hutch scientists were the first to show that a patient's own infection-fighting T cells could, as the sole therapy, put aggressive melanoma in long-term remission through immunotherapy. Hutch research laid the groundwork for the HPV vaccine, which prevents cervical cancer and is poised to save millions of lives worldwide. As many as one in five cancer cases around the world is linked to infections such as HPV, short for human papillomavirus, and our research teams are developing novel ways to treat and prevent them. In 2016, Fred Hutch opened the Bezos Family Immunotherapy Clinic, a first-of-its-kind resource that has more than doubled our capacity to serve patients with leukemias and other cancers, including certain solid tumors, in our immunotherapy clinical trials. Many of the patients seen at the new clinic, including the very first study participant, have gone into complete remission after participating in one of the clinical trials taking place there. Fred Hutch researchers are also delivering targeted therapies to treat solid tumors via our partnership with Seattle Translational Tumor Research (STTR), a multidisciplinary and multi-organizational effort to translate laboratory science into the most precise treatment options for patients with solid tumors. STTR builds on ongoing research on solid tumor cancers that is being performed in basic science, human biology, clinical research and public health science to translate this focused commitment to advance treatment for solid tumors. The Hutchinson Outcomes Research Center (HICOR) is a collaborative research institute at Fred Hutch that facilitates data sharing from providers and patients at Fred Hutch and numerous research institutions to guide improvements in cancer care. HICOR enables data-driven decisions on care consistency and cost-effectiveness that shape program design, best practices and policies that seek to reduce the economic burden of cancer treatment while improving outcomes for patients. We at Fred Hutch will continue to build on and extend our diverse research expertise to deliver the cancer prevention, detection and treatment of tomorrow. We are working toward nothing less than cures.



GlobalGiving


GlobalGiving Badge not earned

GlobalGiving is the largest global crowdfunding community connecting nonprofits, donors, and companies in nearly every country. For donors, GlobalGiving provides an additional layer of vetting and due diligence for each of its nonprofit partners every two years, which may include site visit verification. Learn more about GlobalGiving.

Note: GlobalGiving Badges do not effect the nonprofit’s Impact & Results score.


...   Leadership & Adaptability


Charity Navigator will provide an assessment of the organization’s leadership capacity, strategic planning, and the ability to readily innovate or respond to changes in constituent demand/need or other relevant social and economic conditions to achieve the organization’s mission.


Leadership & Adaptability Score (BETA)

Coming Soon

Encompass Rating Beta V2 does not provide an evaluation of the organization's leadership and adaptability.


Back to Top

...   Culture & Community


Charity Navigator will provide an assessment of the organization’s people operations, connectedness and engagement with the constituents and communities served, and Diversity, Equity and Inclusion measures.


Culture & Community Score (BETA)

Coming Soon

Encompass Rating Beta V2 does not provide an evaluation of the organization's culture and community.


Back to Top